TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cadrenal Therapeutics, Inc. ( (CVKD) ) just unveiled an announcement.
Cadrenal Therapeutics, a late-stage biopharmaceutical firm, has successfully raised $5.1 million through an at-the-market facility, selling over 391,000 shares at $13.15 per share. This capital boost supports the ongoing development of tecarfarin, a new vitamin K antagonist aimed at providing better anticoagulation for patients with cardiac devices or rare cardiovascular conditions. The proceeds also enhance the company’s working capital as it prepares for pivotal clinical trials and explores partnership opportunities.
For detailed information about CVKD stock, go to TipRanks’ Stock Analysis page.